NovoCure (NVCR) Stock May Be Cheap Based On Sales Growth Risk

NovoCure stock has had a strong rebound in recent months, yet long term shareholders are still sitting on a deep drawdown, which makes the current valuation especially important for anyone considering the shares today.

• Over 5 years the share price has declined about 87.5%, which means recent gains have come after a very large fall in value for long term holders.
• Future returns can depend heavily on whether NovoCure converts its tumor treating field technology into consistent revenue growth, while ongoing clinical and commercial execution risk may limit how much investors are willing to pay for that potential.
• On Simply Wall St's broader checks NovoCure screens as relatively cheap, with a high value score of 5 out of 6, suggesting the current market price is low compared with several fundamental yardsticks.

The issue now is whether NovoCure's depressed long term share performance and currently cheap screen leave enough upside potential to justify the risks that come with the stock.

Compare NovoCure's deep value setup with other potential rebound candidates by scanning the hand picked 50 high quality undervalued stocks, which also screen as relatively cheap on key fundamentals.

Does NovoCure Look Undervalued on Sales?

The P/S multiple is often useful for NovoCure because revenue can be more stable than earnings for a company that is still investing heavily and reporting losses. NovoCure currently trades on a P/S of 2.9x, which is very similar to the wider medical equipment industry average of about 2.9x. On a simple sector comparison the stock does not look obviously cheap or expensive.

The picture changes once you factor in the fair P/S ratio that the model estimates at 5.0x for NovoCure, based on its specific mix of growth expectations, margins, size and risk. Against that tailored yardstick, the current 2.9x P/S sits at a clear discount, and the stock would need a much higher sales multiple to line up with that fair ratio.

On this sales based lens NovoCure stock appears undervalued compared with the fair P/S multiple implied by its fundamentals.

See what the numbers say about this price — find out in our valuation breakdown.

The NovoCure Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where NovoCure's valuation puzzle leaves off. They spell out which combinations of future growth, margins and earnings would need to hold for NovoCure's stock to be worth materially more or less than today’s price. Each one treats fair value as a thesis about the business that you can track over time rather than a single static snapshot on the Community page.

The NovoCure community is split between a high-upside recovery story and a cautious view that recent progress may already be reflected in the share price.

Bull case: 64% undervalued

"Analyst consensus expects market expansion from new indications to grow revenues, but the magnitude is likely understated; with overwhelmingly positive real-world responses from top academic centers…"

Read the full Bull Case to see why NovoCure could be undervalued

Bear case: roughly fairly valued

"Early commercial launches for new indications, particularly for non-small cell lung cancer, have shown slower-than-expected prescription growth and a decline in unique prescribers quarter over quarter…"

Read the full Bear Case to see why NovoCure could be overvalued

Do you think there's more to the story for NovoCure? Head over to our Community to see what others are saying!

The Bottom Line

NovoCure screens as undervalued on its tailored sales multiple, which points to a discount that the broader valuation checks also flag as attractive. That gap only really closes if you think the market is correctly pricing in execution and commercial risk around the tumor treating fields platform. The key question now is whether NovoCure can turn its technology into steadier revenue growth that supports a higher and more durable P/S multiple. For investors, the debate is less about spotting the discount and more about whether that discount reflects a genuine opportunity or a value trap if progress stalls.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com